What Does HER2-Positive Mean for Esophageal Cancer?

When a doctor says your esophageal cancer is HER2-positive, it means your tumor cells overproduce a specific protein called human epidermal growth factor receptor 2 (HER2) or have extra copies of the HER2 gene ^[1]. HER2 is a protein that normally helps cells grow and divide. In some cancers, having too much of this protein can make cancer cells grow faster ^{[1] [2]}.

Discovering that a tumor is HER2-positive is clinically useful information because it opens the door to targeted therapies—drugs that specifically find and attack those cells ^[3].

How HER2 is Tested

HER2 is a biomarker—a measurable feature in your tumor tissue. Pathologists typically test for HER2 using a sample from a biopsy or surgery. They usually start with a test called immunohistochemistry (IHC), which stains the tissue to measure the amount of HER2 protein. The result is given a score from 0 to 3+.

• A score of 3+ is considered HER2-positive.
• A score of 2+ is borderline, so a second test called in-situ hybridization (ISH or FISH) is done to check for extra copies of the HER2 gene (called gene amplification). If the ISH test shows amplification, the tumor is considered HER2-positive ^{[1] [2]}.

Note: HER2 status is a feature of the tumor tissue; it is not a cancer stage and does not tell you if the cancer has spread. It is also not typically an inherited genetic mutation that affects your family.

How HER2-Positive Status Affects Your Treatment

A HER2-positive result does not mean you will automatically receive a specific drug. Whether a HER2-targeted therapy is right for you depends heavily on your cancer stage, exact tumor location, and cancer type (histology).

• Cancer Type: HER2-positive tumors are most commonly found in adenocarcinoma of the gastroesophageal (GE) junction (where the esophagus meets the stomach) or the lower esophagus. It is much less common in squamous cell carcinoma, a different type of esophageal cancer ^{[1] [4]}.
• Stage of Disease: The strongest evidence and regulatory approvals for HER2-targeted treatments are for advanced, unresectable (cannot be removed by surgery), or metastatic adenocarcinoma ^{[3] [4]}. Treatment for early-stage, localized cancer is different and may not include HER2 drugs.

If you have advanced or metastatic HER2-positive adenocarcinoma, your doctor may recommend adding trastuzumab (Herceptin) to your chemotherapy ^{[3] [5]}. Trastuzumab blocks the growth signals of the HER2 protein. Depending on another biomarker score called PD-L1 (often reported as a Combined Positive Score or CPS), doctors might also add immunotherapy, such as pembrolizumab, to the combination of trastuzumab and chemotherapy ^{[6] [7]}.

If the cancer progresses after initial treatment, other drugs like trastuzumab deruxtecan (Enhertu) might be considered for advanced GE junction adenocarcinoma, though availability depends on local approvals and prior treatments ^{[8] [9]}.

Understanding the Risks and Side Effects

While targeted therapies are designed to focus on cancer cells, they can still injure healthy tissues and cause serious side effects:

• Trastuzumab can cause infusion reactions and weaken the heart muscle. Patients require baseline and periodic heart monitoring (like an echocardiogram) while on this drug ^[5].
• Trastuzumab deruxtecan carries a serious, potentially fatal risk of severe lung inflammation called interstitial lung disease (ILD) or pneumonitis, as well as risks for nausea and low blood counts ^[10].

Patients on these treatments should promptly report new symptoms—especially a new cough, shortness of breath, fever, chest pain, rapid weight gain, or swelling—to their oncology team immediately ^[10].

Can HER2 Status Change?

Cancer is biologically complex (heterogeneous), meaning different parts of the same tumor might have different HER2 scores, or the cancer might change after treatment ^{[11] [12]}. If your cancer progresses, your doctor might discuss repeating a biopsy to check your current HER2 status, provided a new sample can be safely obtained and the results would change your treatment plan ^[13].